

Special Issue

The 10th Anniversary of *Vaccines*—Cancer Vaccines and Immunotherapy

Message from the Guest Editor

In 2022, we will celebrate the 10th anniversary volume of the journal *Vaccines* (ISSN 2076-393X). *Vaccines* is an international, peer-reviewed, quick-refereeing, open access journal published online by MDPI, Basel, Switzerland. *Vaccines* is indexed by SCIE, PubMed (NLM), as well as others. The Impact Factor for this journal is 4.422, and it ranks 74/162 (Q2) in “Immunology” and 63/140 (Q2) in “Medicine, Research & Experimental Pharmacology” in Web of Science. The inaugural issue was released in 2013, and in 2020, we published the 1000th paper in this journal. In 2021, we achieved our goal of publishing 1200 papers in one year. *Vaccines* is definitely a rapidly developing journal. This Special Issue will include high-quality papers on topics within the broad scope of *Vaccines*. We will consider manuscripts that investigate immunology and vaccinology against cancer. It is our pleasure to invite you to contribute an original research paper or a comprehensive review article for peer review and possible publication in *Vaccines*.

Guest Editor

Prof. Dr. Subbaya Subramanian

Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

closed (31 March 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/114042

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).